BMS-986504
As of the edition of 20 October 2026, BMS-986504 is a drug known only by a code name: in active development; acts on PRMT5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 9, 0 stopped early
- Disease areas
- Cancer; Nervous system; Digestive system; Hormones; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PRMT5 | Protein arginine N-methyltransferase 5 | O14744 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 0 | 4 | 0 |
| Phase 2 | 5 | 0 | 5 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2025 to now |